ADAGIO-Lipids gives promises but faces the setbacks.
Taskinen
Marja-Riitta
MR
D052242:Adiponectin / Q000097:blood; D050154:Adiposity / Q000187:drug effects; D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002097:C-Reactive Protein / Q000378:metabolism; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007328:Insulin / Q000097:blood; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000378:metabolism; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D000077285:Rimonabant; D013997:Time Factors; D016896:Treatment Outcome
C499918:ADIPOQ protein, human; D052242:Adiponectin; D019440:Anti-Obesity Agents; D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D002097:C-Reactive Protein; D000077285:Rimonabant